Modalis Therapeutics : Business Plans and Matters Related to High Growth Potential

English translation for reference purposes only

FY2022 Business Plans and

Matters Related to High Growth Potential

（TSE︓4883）

In case of any discrepancy, the Japanese version shall prevail

Modalis therapeutics Corporation

March 29 , 2022

CCooppyyrirgighhttaannddpproropprireietataryrytotoMooddaalilsis

Disclaimer

This document has been prepared by Modalis Therapeutics corporation and Modalis Therapeutics Inc. (the "Companies") solely for information purpose only. This document does not constitute or form part of and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Companies in Japan, the United States or any other jurisdictions. The information contained herein is based on current economic, regulatory, market trends and other conditions. The Companies make no representation or guarantee with respect to the credibility, accuracy or completeness of the information herein. The information contained herein may change without prior notice. You may not publish or use this document and the contents thereof for any other purpose without a prior written consent of the Companies. Furthermore, the information on future business results are forward-looking statements. Forward-looking statements include but not limited to expressions such as "believe", "expect", "plan", "strategic", "expect", "anticipate", "predict" and "possibility", as well as other similar expressions to explain future business activities, achievements, events and future conditions. Forward-looking statements are predictions about the future that reflect management's judgment based on currently available information. As such, these forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed in or suggested by the forward-looking statements. Therefore, you may not rely entirely on forward-looking statements. The Companies do not assume any obligation to change or correct any forward-looking statements in light of new information, future events or other findings.

This document and its contents are confidential and are being provided to you solely for your information and may not be retransmitted. This presentation is being furnished to you solely for your information and may not be reproduced or redistributed to any other person. In giving this presentation, the Companies do not undertake any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent.

Information on companies other than the Companies and information provided from third parties are based on public information or sources. The Companies have not independently verified the accuracy and appropriateness of such data and indicators used herein, nor assume any responsibility for the accuracy and appropriateness of such data and indicators presented in this document.

Table of contents

• 1. Corporate Overview

• 2. Gene Therapy, Gene Editing

• 3. CRISPR-GNDM® and its advantages

• 4. Key Topics

  MDL-101 for CMD1A MDL-104 for Tau

  MDL-206 for Angelman Syndrome

  Set new target area and incubate a few pipelines

• 5. Growth Strategy

• 6. Risk Information

1. Corporate Overview

1. Corporate Overview︓Modalis

• • pioneering the first CRISPR-based gene modulation technology

• • leading company in epigenetic modulation

• • develops novel precision medicines for a genetic disorders for which there have been no cure

MODALIS